Mostrar el registro sencillo del ítem

dc.contributor.authorBueno, Hector 
dc.contributor.authorGoñi, Clara
dc.contributor.authorSalguero-Bodes, Rafael
dc.contributor.authorPalacios, Beatriz
dc.contributor.authorVicent, Lourdes
dc.contributor.authorMoreno, Guillermo
dc.contributor.authorRosillo, Nicolás
dc.contributor.authorVarela, Luis
dc.contributor.authorCapel, Margarita
dc.contributor.authorDelgado, Juan
dc.contributor.authorArribas, Fernando
dc.contributor.authorDel Oro, Manuel
dc.contributor.authorOrtega, Carmen
dc.contributor.authorBernal, Jose L
dc.date.accessioned2023-03-16T09:55:18Z
dc.date.available2023-03-16T09:55:18Z
dc.date.issued2022
dc.identifier.citationFront Cardiovasc Med. 2022 Mar 17;9:818525es_ES
dc.identifier.issn2297-055Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/15639
dc.description.abstractThere is scarce information on patients with secondary heart failure diagnosis (sHF). We aimed to compare the characteristics, burden, and outcomes of sHF with those with primary HF diagnosis (pHF). Retrospective, observational study on patients ≥18 years with emergency department (ED) visits during 2018 with pHF and sHF in ED or hospital (ICD-10-CM) diagnostic codes. Baseline characteristics, 30-day and 1-year mortality, readmission and re-ED visit rates, and costs were compared between sHF and pHF. Out of the 797 patients discharged home from the ED, 45.5% had sHF, and these presented lower 1-year hospitalization, re-ED visit rates, and costs. In contrast, out of the 2,286 hospitalized patients, 55% had sHF and 45% pHF. Hospitalized sHF patients had significantly (p < 0.01) greater comorbidity, lower use of recommended HF therapies, longer length of stay (10.8 ± 10.1 vs. 9.7 ± 7.9 days), and higher in-hospital and 1-year mortality (32 vs. 25.8%) with no significant differences in readmission rates and lower 1-year re-ED visit rate. Hospitalized sHF patients had higher total costs (€12,262,422 vs. €9,144,952, p < 0.001), mean cost per patient-year (€9,755 ± 13,395 vs. €8,887 ± 12,059), and average daily cost per patient. Hospitalized sHF patients have a worse initial prognosis, greater use of healthcare resources, and higher costs.es_ES
dc.description.sponsorshipThis study was an investigator-initiated initiative sponsored and supported by the grant from AstraZeneca Spain. LV receives research funding from the Instituto de Salud Carlos III, Spain (CM20/00104). GM is supported by a pre-doctoral grant by the Spanish Ministry of Education (FPU18/03606).es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titlePrimary vs. Secondary Heart Failure Diagnosis: Differences in Clinical Outcomes, Healthcare Resource Utilization and Cost.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35369321es_ES
dc.format.volume9es_ES
dc.format.page818525es_ES
dc.identifier.doi10.3389/fcvm.2022.818525es_ES
dc.contributor.funderAstraZeneca es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversion10.3389/fcvm.2022.818525es_ES
dc.identifier.journalFrontiers in cardiovascular medicinees_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Investigación Cardiovascular Traslacional Multidisciplinariaes_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CM20/00104es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FPU18/03606es_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional